Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Oligodendroglioma 1Neurocytoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Astrocytoma 1

Interventions

blinatumomab 2Vincristine 2Rituximab 2Methotrexate 2Cytarabine 2Cyclophosphamide 2prednylidene 1pegaspargase 1merphos 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1azathiopurine 1auricularum 1X-Rays 1Stem Cell Transplantation 1Spinal Puncture 1Specimen Handling 1Prednisone 1Phantoms, Imaging 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Mercaptopurine 1Leucovorin 1Etoposide 1Doxorubicin 1Dexamethasone 1Daunorubicin 1Calcium Dobesilate 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Burkitt Lymphoma × Vincristine × Clear all
NCT02003222 2026-05-01

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01516580 2026-02-09

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Completed
482 enrolled 1 FDA
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡